Global Metabolic Disorder Therapeutics Market Insights and Forecast to 2028

Report ID: 1530403 | Published Date: Jan 2025 | No. of Page: 113 | Base Year: 2024 | Rating: 4.5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Lysosomal Storage Diseases
        1.2.3 Diabetes
        1.2.4 Obesity
        1.2.5 Inherited Metabolic Disorders
        1.2.6 Hypercholesterolemia
    1.3 Market by Application
        1.3.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Oral
        1.3.3 Parenteral
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Metabolic Disorder Therapeutics Market Perspective (2017-2028)
    2.2 Metabolic Disorder Therapeutics Growth Trends by Region
        2.2.1 Metabolic Disorder Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2017-2022)
        2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2023-2028)
    2.3 Metabolic Disorder Therapeutics Market Dynamics
        2.3.1 Metabolic Disorder Therapeutics Industry Trends
        2.3.2 Metabolic Disorder Therapeutics Market Drivers
        2.3.3 Metabolic Disorder Therapeutics Market Challenges
        2.3.4 Metabolic Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Metabolic Disorder Therapeutics Players by Revenue
        3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2017-2022)
        3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2017-2022)
    3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
    3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio
        3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2021
    3.5 Metabolic Disorder Therapeutics Key Players Head office and Area Served
    3.6 Key Players Metabolic Disorder Therapeutics Product Solution and Service
    3.7 Date of Enter into Metabolic Disorder Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disorder Therapeutics Breakdown Data by Type
    4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2017-2022)
    4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2023-2028)
5 Metabolic Disorder Therapeutics Breakdown Data by Application
    5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2017-2022)
    5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Metabolic Disorder Therapeutics Market Size (2017-2028)
    6.2 North America Metabolic Disorder Therapeutics Market Size by Type
        6.2.1 North America Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
        6.2.2 North America Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
        6.2.3 North America Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
    6.3 North America Metabolic Disorder Therapeutics Market Size by Application
        6.3.1 North America Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
        6.3.2 North America Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
        6.3.3 North America Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
    6.4 North America Metabolic Disorder Therapeutics Market Size by Country
        6.4.1 North America Metabolic Disorder Therapeutics Market Size by Country (2017-2022)
        6.4.2 North America Metabolic Disorder Therapeutics Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Metabolic Disorder Therapeutics Market Size (2017-2028)
    7.2 Europe Metabolic Disorder Therapeutics Market Size by Type
        7.2.1 Europe Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
        7.2.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
        7.2.3 Europe Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
    7.3 Europe Metabolic Disorder Therapeutics Market Size by Application
        7.3.1 Europe Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
        7.3.2 Europe Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
        7.3.3 Europe Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
    7.4 Europe Metabolic Disorder Therapeutics Market Size by Country
        7.4.1 Europe Metabolic Disorder Therapeutics Market Size by Country (2017-2022)
        7.4.2 Europe Metabolic Disorder Therapeutics Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size (2017-2028)
    8.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type
        8.2.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
    8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application
        8.3.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
    8.4 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region
        8.4.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Metabolic Disorder Therapeutics Market Size (2017-2028)
    9.2 Latin America Metabolic Disorder Therapeutics Market Size by Type
        9.2.1 Latin America Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
        9.2.2 Latin America Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
        9.2.3 Latin America Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
    9.3 Latin America Metabolic Disorder Therapeutics Market Size by Application
        9.3.1 Latin America Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
        9.3.2 Latin America Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
        9.3.3 Latin America Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
    9.4 Latin America Metabolic Disorder Therapeutics Market Size by Country
        9.4.1 Latin America Metabolic Disorder Therapeutics Market Size by Country (2017-2022)
        9.4.2 Latin America Metabolic Disorder Therapeutics Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size (2017-2028)
    10.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type
        10.2.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Metabolic Disorder Therapeutics Market Share by Type (2017-2028)
    10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application
        10.3.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Metabolic Disorder Therapeutics Market Share by Application (2017-2028)
    10.4 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country
        10.4.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Novo Nordisk A/S
        11.1.1 Novo Nordisk A/S Company Details
        11.1.2 Novo Nordisk A/S Business Overview
        11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
        11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.1.5 Novo Nordisk A/S Recent Developments
    11.2 Sanofi S.A.
        11.2.1 Sanofi S.A. Company Details
        11.2.2 Sanofi S.A. Business Overview
        11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
        11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.2.5 Sanofi S.A. Recent Developments
    11.3 Boehringer Ingelheim GmbH
        11.3.1 Boehringer Ingelheim GmbH Company Details
        11.3.2 Boehringer Ingelheim GmbH Business Overview
        11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
        11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.3.5 Boehringer Ingelheim GmbH Recent Developments
    11.4 Eli Lilly and Company
        11.4.1 Eli Lilly and Company Company Details
        11.4.2 Eli Lilly and Company Business Overview
        11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
        11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.4.5 Eli Lilly and Company Recent Developments
    11.5 Merck KgaA
        11.5.1 Merck KgaA Company Details
        11.5.2 Merck KgaA Business Overview
        11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
        11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.5.5 Merck KgaA Recent Developments
    11.6 Amgen, Inc.
        11.6.1 Amgen, Inc. Company Details
        11.6.2 Amgen, Inc. Business Overview
        11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
        11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.6.5 Amgen, Inc. Recent Developments
    11.7 AstraZeneca PLC
        11.7.1 AstraZeneca PLC Company Details
        11.7.2 AstraZeneca PLC Business Overview
        11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
        11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.7.5 AstraZeneca PLC Recent Developments
    11.8 Actelion Pharmaceuticals Ltd.
        11.8.1 Actelion Pharmaceuticals Ltd. Company Details
        11.8.2 Actelion Pharmaceuticals Ltd. Business Overview
        11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
        11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.8.5 Actelion Pharmaceuticals Ltd. Recent Developments
    11.9 Shire PLC
        11.9.1 Shire PLC Company Details
        11.9.2 Shire PLC Business Overview
        11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
        11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.9.5 Shire PLC Recent Developments
    11.10 AbbVie, Inc.
        11.10.1 AbbVie, Inc. Company Details
        11.10.2 AbbVie, Inc. Business Overview
        11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
        11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.10.5 AbbVie, Inc. Recent Developments
    11.11 Biocon Ltd.
        11.11.1 Biocon Ltd. Company Details
        11.11.2 Biocon Ltd. Business Overview
        11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
        11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.11.5 Biocon Ltd. Recent Developments
    11.12 BioMarin Pharmaceutical, Inc.
        11.12.1 BioMarin Pharmaceutical, Inc. Company Details
        11.12.2 BioMarin Pharmaceutical, Inc. Business Overview
        11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
        11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.12.5 BioMarin Pharmaceutical, Inc. Recent Developments
    11.13 Bristol-Myers Squibb Company
        11.13.1 Bristol-Myers Squibb Company Company Details
        11.13.2 Bristol-Myers Squibb Company Business Overview
        11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
        11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.13.5 Bristol-Myers Squibb Company Recent Developments
    11.14 Cipla, Inc.
        11.14.1 Cipla, Inc. Company Details
        11.14.2 Cipla, Inc. Business Overview
        11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
        11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.14.5 Cipla, Inc. Recent Developments
    11.15 CymaBay Therapeutics, Inc.
        11.15.1 CymaBay Therapeutics, Inc. Company Details
        11.15.2 CymaBay Therapeutics, Inc. Business Overview
        11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
        11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022)
        11.15.5 CymaBay Therapeutics, Inc. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Lysosomal Storage Diseases
    Table 3. Key Players of Diabetes
    Table 4. Key Players of Obesity
    Table 5. Key Players of Inherited Metabolic Disorders
    Table 6. Key Players of Hypercholesterolemia
    Table 7. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Metabolic Disorder Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Metabolic Disorder Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Metabolic Disorder Therapeutics Market Share by Region (2017-2022)
    Table 11. Global Metabolic Disorder Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Metabolic Disorder Therapeutics Market Share by Region (2023-2028)
    Table 13. Metabolic Disorder Therapeutics Market Trends
    Table 14. Metabolic Disorder Therapeutics Market Drivers
    Table 15. Metabolic Disorder Therapeutics Market Challenges
    Table 16. Metabolic Disorder Therapeutics Market Restraints
    Table 17. Global Metabolic Disorder Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Metabolic Disorder Therapeutics Revenue Share by Players (2017-2022)
    Table 19. Global Top Metabolic Disorder Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2021)
    Table 20. Ranking of Global Top Metabolic Disorder Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Metabolic Disorder Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Metabolic Disorder Therapeutics Product Solution and Service
    Table 24. Date of Enter into Metabolic Disorder Therapeutics Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Metabolic Disorder Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2017-2022)
    Table 28. Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2023-2028)
    Table 30. Global Metabolic Disorder Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Metabolic Disorder Therapeutics Revenue Share by Application (2017-2022)
    Table 32. Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Metabolic Disorder Therapeutics Revenue Share by Application (2023-2028)
    Table 34. North America Metabolic Disorder Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 35. North America Metabolic Disorder Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 36. North America Metabolic Disorder Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 37. North America Metabolic Disorder Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 38. North America Metabolic Disorder Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Metabolic Disorder Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Metabolic Disorder Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 41. Europe Metabolic Disorder Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 42. Europe Metabolic Disorder Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 43. Europe Metabolic Disorder Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 44. Europe Metabolic Disorder Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Metabolic Disorder Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Metabolic Disorder Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Metabolic Disorder Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Metabolic Disorder Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Metabolic Disorder Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Metabolic Disorder Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Metabolic Disorder Therapeutics Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Metabolic Disorder Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 53. Latin America Metabolic Disorder Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 54. Latin America Metabolic Disorder Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 55. Latin America Metabolic Disorder Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 56. Latin America Metabolic Disorder Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Metabolic Disorder Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Metabolic Disorder Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Metabolic Disorder Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Metabolic Disorder Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Metabolic Disorder Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Metabolic Disorder Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Metabolic Disorder Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 64. Novo Nordisk A/S Company Details
    Table 65. Novo Nordisk A/S Business Overview
    Table 66. Novo Nordisk A/S Metabolic Disorder Therapeutics Product
    Table 67. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 68. Novo Nordisk A/S Recent Developments
    Table 69. Sanofi S.A. Company Details
    Table 70. Sanofi S.A. Business Overview
    Table 71. Sanofi S.A. Metabolic Disorder Therapeutics Product
    Table 72. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 73. Sanofi S.A. Recent Developments
    Table 74. Boehringer Ingelheim GmbH Company Details
    Table 75. Boehringer Ingelheim GmbH Business Overview
    Table 76. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product
    Table 77. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 78. Boehringer Ingelheim GmbH Recent Developments
    Table 79. Eli Lilly and Company Company Details
    Table 80. Eli Lilly and Company Business Overview
    Table 81. Eli Lilly and Company Metabolic Disorder Therapeutics Product
    Table 82. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 83. Eli Lilly and Company Recent Developments
    Table 84. Merck KgaA Company Details
    Table 85. Merck KgaA Business Overview
    Table 86. Merck KgaA Metabolic Disorder Therapeutics Product
    Table 87. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 88. Merck KgaA Recent Developments
    Table 89. Amgen, Inc. Company Details
    Table 90. Amgen, Inc. Business Overview
    Table 91. Amgen, Inc. Metabolic Disorder Therapeutics Product
    Table 92. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 93. Amgen, Inc. Recent Developments
    Table 94. AstraZeneca PLC Company Details
    Table 95. AstraZeneca PLC Business Overview
    Table 96. AstraZeneca PLC Metabolic Disorder Therapeutics Product
    Table 97. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 98. AstraZeneca PLC Recent Developments
    Table 99. Actelion Pharmaceuticals Ltd. Company Details
    Table 100. Actelion Pharmaceuticals Ltd. Business Overview
    Table 101. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product
    Table 102. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 103. Actelion Pharmaceuticals Ltd. Recent Developments
    Table 104. Shire PLC Company Details
    Table 105. Shire PLC Business Overview
    Table 106. Shire PLC Metabolic Disorder Therapeutics Product
    Table 107. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 108. Shire PLC Recent Developments
    Table 109. AbbVie, Inc. Company Details
    Table 110. AbbVie, Inc. Business Overview
    Table 111. AbbVie, Inc. Metabolic Disorder Therapeutics Product
    Table 112. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 113. AbbVie, Inc. Recent Developments
    Table 114. Biocon Ltd. Company Details
    Table 115. Biocon Ltd. Business Overview
    Table 116. Biocon Ltd. Metabolic Disorder Therapeutics Product
    Table 117. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 118. Biocon Ltd. Recent Developments
    Table 119. BioMarin Pharmaceutical, Inc. Company Details
    Table 120. BioMarin Pharmaceutical, Inc. Business Overview
    Table 121. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product
    Table 122. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 123. BioMarin Pharmaceutical, Inc. Recent Developments
    Table 124. Bristol-Myers Squibb Company Company Details
    Table 125. Bristol-Myers Squibb Company Business Overview
    Table 126. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product
    Table 127. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 128. Bristol-Myers Squibb Company Recent Developments
    Table 129. Cipla, Inc. Company Details
    Table 130. Cipla, Inc. Business Overview
    Table 131. Cipla, Inc. Metabolic Disorder Therapeutics Product
    Table 132. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 133. Cipla, Inc. Recent Developments
    Table 134. CymaBay Therapeutics, Inc. Company Details
    Table 135. CymaBay Therapeutics, Inc. Business Overview
    Table 136. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product
    Table 137. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2017-2022) & (US$ Million)
    Table 138. CymaBay Therapeutics, Inc. Recent Developments
    Table 139. Research Programs/Design for This Report
    Table 140. Key Data Information from Secondary Sources
    Table 141. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Metabolic Disorder Therapeutics Market Share by Type: 2021 VS 2028
    Figure 2. Lysosomal Storage Diseases Features
    Figure 3. Diabetes Features
    Figure 4. Obesity Features
    Figure 5. Inherited Metabolic Disorders Features
    Figure 6. Hypercholesterolemia Features
    Figure 7. Global Metabolic Disorder Therapeutics Market Share by Application: 2021 VS 2028
    Figure 8. Oral Case Studies
    Figure 9. Parenteral Case Studies
    Figure 10. Others Case Studies
    Figure 11. Metabolic Disorder Therapeutics Report Years Considered
    Figure 12. Global Metabolic Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 13. Global Metabolic Disorder Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Metabolic Disorder Therapeutics Market Share by Region: 2021 VS 2028
    Figure 15. Global Metabolic Disorder Therapeutics Market Share by Players in 2021
    Figure 16. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2021)
    Figure 17. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2021
    Figure 18. North America Metabolic Disorder Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 19. North America Metabolic Disorder Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 20. North America Metabolic Disorder Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 21. North America Metabolic Disorder Therapeutics Market Size Share by Country (2017-2028)
    Figure 22. United States Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Canada Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Europe Metabolic Disorder Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 25. Europe Metabolic Disorder Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 26. Europe Metabolic Disorder Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 27. Europe Metabolic Disorder Therapeutics Market Size Share by Country (2017-2028)
    Figure 28. Germany Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. France Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. U.K. Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Italy Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Russia Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Nordic Countries Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 35. Asia Pacific Metabolic Disorder Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 36. Asia Pacific Metabolic Disorder Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 37. Asia Pacific Metabolic Disorder Therapeutics Market Size Share by Region (2017-2028)
    Figure 38. China Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. South Korea Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. India Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Australia Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Latin America Metabolic Disorder Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 45. Latin America Metabolic Disorder Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 46. Latin America Metabolic Disorder Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 47. Latin America Metabolic Disorder Therapeutics Market Size Share by Country (2017-2028)
    Figure 48. Mexico Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Brazil Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Metabolic Disorder Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 51. Middle East and Africa Metabolic Disorder Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 52. Middle East and Africa Metabolic Disorder Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 53. Middle East and Africa Metabolic Disorder Therapeutics Market Size Share by Country (2017-2028)
    Figure 54. Turkey Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Saudi Arabia Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. UAE Metabolic Disorder Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 58. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 59. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 60. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 61. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 62. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 63. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 64. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 65. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 66. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 67. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 68. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 69. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 70. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 71. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2017-2022)
    Figure 72. Bottom-up and Top-down Approaches for This Report
    Figure 73. Data Triangulation
    Figure 74. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Frequently Asked Questions
Metabolic Disorder Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Metabolic Disorder Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Metabolic Disorder Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports